[18F] Fluoroestradiol PET/CT Imaging for the Detection of Estrogen Receptor in Patients with Recurrent or Metastatic Uterine Cancer
This phase II trial evaluates a radioactive imaging drug called 18F-fluoroestradiol (18F-FES) that is injected into the body, to detect estrogen receptor positive in patients with uterine cancer that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic) using an imaging procedure called positron emission tomography/computed tomography (PET/CT). Estrogen is a naturally occurring hormone in the body. In some cancers (such as breast cancer and uterine cancer) the cancer cells may have estrogen receptors and can use the naturally occurring estrogen to help the cancer cells grow. In these cancers there are a number of treatments that may target the estrogen receptors or the amount of estrogen in the body to help treat the cancer. Some uterine cancers have also been shown to have estrogen receptors, however, the effectiveness of treating with estrogen targeted drugs is less well understood. 18F-FES is a specialized radioactive imaging drug used to create computerized pictures or images of areas where your doctors think you have active metastasized uterine tumor that might have estrogen receptors. PET scan is an imaging test that allows your doctor to check for diseases in your body, including cancer. The scan uses a radioactive imaging drug (sometimes called a radiotracer or radiopharmaceutical) that is injected into a vein in your arm. The imaging drug is attracted to and taken into certain cells in your body, including cancer cells. Because of this uptake, cancer cells show up as bright spots on PET scans. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. This study may help researchers learn whether 18F-FES PET/CT can detect estrogen receptor positive in patients with recurrent or metastatic uterine cancer.